Recent News

• 10.06.2025 - Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX’ Reflecting Digital Asset Treasury Strategy
• 09.29.2025 - Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation
• 08.14.2025 - Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
• 07.24.2025 - Applied DNA Announces New Follow-On LineaDNA™ Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application
• 07.07.2025 - Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
• 06.30.2025 - Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
• 06.17.2025 - Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward

Recent Filings

• 10.01.2025 - 8-K Current report
• 10.01.2025 - EX-99.1 EX-99.1
• 09.29.2025 - 8-K Current report
• 09.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.25.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 07.07.2025 - 8-K Current report